# BioTroy Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/biotroy-therapeutics

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.biotroytherapeutics.cn
- Latest round: Series A (Jun 17, 2025)
- Investors on record: 6

## About

Established in 2020 and based in Shanghai, China, BioTroy Therapeutics has built BioTroy Engine, an integrated platform for new tumor immune target discovery. Jie Xu, the founder of the company, has studied and discovered new pathway regulation mechanisms such as PD-1/PD-L1, p53, MAPK, NFKB, WNT, and RhoGAP. In June 2025, BioTroy Therapeutics raised a series A funding led by new investor Lapam Capital, with participation from other new investors Shanghai Sci-Tech Innovation Center Capital, Pudong Venture Capital and returning investors Shanghai Healthcare Capital and Co-Win Ventures. The company has completed platform construction for target biology, antibody discovery and upstream process development, and based on the BioTroy Engine, the company has identified a series of first-in-class IO targets including BT1 and BT2, which can be enabled advanced level of immunosuppression against lung cancer, breast cancer, colorectal cancer and other high incidence of solid tumors. And also, the company has identified four receptors that can be bound by the BT1 target, by developing monoclonal antibodies against BT1 targets, we can effectively block the binding of BT1 targets and downstream receptors, thereby relieving the inhibition of BT1 on T cells and inhibiting the production of Treg and MDSC, can bring a solution to the current clinical PD-(L)1 ineffective and drug-resistant people.

## Funding rounds

- Series A, Jun 17, 2025 — Co-Win Ventures, Lapam Capital, Shanghai Sci-Tech Innovation Center Capital, Pudong Venture Capital, Shanghai Healthcare Capital
- Angel, Jan 19, 2022 — Shanghai Healthcare Capital, Atlatl

## Investors

- Shanghai Healthcare Capital (https://capitalatlas.ai/funds/shanghai-healthcare-capital) — Angel, Series A
- Atlatl — Angel
- Co-Win Ventures (https://capitalatlas.ai/funds/co-win-ventures) — Series A
- Lapam Capital (https://capitalatlas.ai/funds/lapam-capital) — Series A
- Shanghai Sci-Tech Innovation Center Capital (https://capitalatlas.ai/funds/shanghai-sci-tech-innovation-center-capital) — Series A
- Pudong Venture Capital (https://capitalatlas.ai/funds/pudong-venture-capital) — Series A